should avastin be added to egfr tki therapy for egfr mutation-positive nsclc?
Published 8 years ago • 286 plays • Length 7:48Download video MP4
Download video MP3
Similar videos
-
5:09
should a third generation egfr inhibitor be first line therapy for egfr mutation-positive nsclc?
-
2:21
should egfr tki therapy be continued beyond progression?
-
9:26
adding avastin to tarceva help egfr positive lung cancer patients?
-
3:28
should third generation egfr inhibitors be used before or after progression?
-
17:45
individual treatments for individual egfr mutations
-
7:59
dacomitinib beats iressa as first line treatment for egfr mutation-positive nsclc
-
14:43
gracecast-070_lung-cancer_q&a for acquired egfr tki and re-biopsying
-
3:15
does the specific egfr mutation matter when choosing an oral egfr inhibitor?
-
3:25
are there significant differences among the 1st and 2nd generation egfr tkis?
-
6:06
the adaura trial: the effect on egfr treatment - targeted therapies in lung cancer 2023
-
33:47
gracecast-049_lung-cancer_weiss on egfr therapy for early stage nsclc
-
2:47
treating egfr patients after tarceva stops working
-
28:22
gracecast-088_lung-cancer_challenging cases in lung cancer: acquired resistance to egfr tki therapy
-
12:58
egfr inhibitor therapy in second line
-
8:49
grace targeted therapies lung cancer 2021 - a role for chemo io in patients with egfr mutations?
-
7:12
case based panel discussion - egfr - chemotherapy and egfr inhibitor concurrently or sequentially?
-
5:18
case based panel discussion - egfr mutation -the recommended treatment for common egfr mutations
-
6:26
metastatic egfr nsclc: recent developments - targeted therapies in lung cancer 2023
-
6:10
case based panel discussion - what is the recommended treatment for common egfr mutations